da Silva, Wânia Cristina http://orcid.org/0000-0002-5108-5724
de Araujo, Vânia Eloisa http://orcid.org/0000-0002-0345-8522
Lima, Ellias Magalhães e Abreu
dos Santos, Jessica Barreto Ribeiro http://orcid.org/0000-0002-5528-0658
Silva, Michael Ruberson Ribeiro da http://orcid.org/0000-0003-2550-7249
Almeida, Paulo Henrique Ribeiro Fernandes http://orcid.org/0000-0002-9369-0690
de Assis Acurcio, Francisco http://orcid.org/0000-0002-5880-5261
Godman, Brian http://orcid.org/0000-0001-6539-6972
Kurdi, Amanj http://orcid.org/0000-0001-5036-1988
Cherchiglia, Mariângela Leal http://orcid.org/0000-0001-5622-567X
Andrade, Eli Iola Gurgel http://orcid.org/0000-0002-0206-2462
Funding for this research was provided by:
National Scientific and Technological Development Council
Article History
First Online: 30 November 2018
Compliance with Ethical Standards
:
: The research was supported by the Research Group on Pharmacoepidemiology (GPFE), <i>Centro Colaborador do SUS</i> (CCATES) and Research Group on Health Economics (GPES) of UFMG. This systematic review is an integral part of the research project “Economic evaluation of monoclonal antibody treatments in metastatic colorectal cancer,” with financial support from the National Council for Scientific and Technological Development (CNPq), the Minas Gerais State Agency for Research and Development (FAPEMIG) and the Coordination for the Improvement of Higher Education Personnel (CAPES).
: Wânia Cristina da Silva, Vânia Eloisa de Araujo, Ellias Magalhães e Abreu Lima, Jessica Barreto Ribeiro dos Santos, Michael Ruberson Ribeiro da Silva, Paulo Henrique Ribeiro Fernandes Almeida, Francisco de Assis Acurcio, Brian Godman, Amanj Kurdi, Mariângela Leal Cherchiglia, and Eli Iola Gurgel Andrade declare that they have no conflicts of interest that might influence the results of the investigation.
: All the papers incorporated into this systematic review and meta-analysis have been fully referenced.